Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".

Perrotti D, Agarwal A, Lucas CM, Narla G, Neviani P, Odero MD, Ruvolo PP, Verrills NM.

Sci Transl Med. 2019 Jul 17;11(501). pii: eaau0416. doi: 10.1126/scitranslmed.aau0416.

PMID:
31316003
2.

LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML.

Ruvolo PP, Hu CW, Qiu Y, Ruvolo VR, Go RL, Hubner SE, Coombes KR, Andreeff M, Qutub AA, Kornblau SM.

EBioMedicine. 2019 Jun;44:126-137. doi: 10.1016/j.ebiom.2019.05.025. Epub 2019 May 16.

3.

Galectins as regulators of cell survival in the leukemia niche.

Ruvolo PP.

Adv Biol Regul. 2019 Jan;71:41-54. doi: 10.1016/j.jbior.2018.09.003. Epub 2018 Sep 12. Review.

PMID:
30245264
4.

Role of protein phosphatases in the cancer microenvironment.

Ruvolo PP.

Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):144-152. doi: 10.1016/j.bbamcr.2018.07.006. Epub 2018 Jul 17. Review.

PMID:
30026077
5.

Role of MSC-derived galectin 3 in the AML microenvironment.

Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N Jr, Zeng Z, McQueen T, Daver N, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M.

Biochim Biophys Acta Mol Cell Res. 2018 Jul;1865(7):959-969. doi: 10.1016/j.bbamcr.2018.04.005. Epub 2018 Apr 12.

6.

Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival.

Kornblau SM, Ruvolo PP, Wang RY, Battula VL, Shpall EJ, Ruvolo VR, McQueen T, Qui Y, Zeng Z, Pierce S, Jacamo R, Yoo SY, Le PM, Sun J, Hail N Jr, Konopleva M, Andreeff M.

Haematologica. 2018 May;103(5):810-821. doi: 10.3324/haematol.2017.172429. Epub 2018 Mar 15.

7.

Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.

Abrams SL, Ruvolo PP, Ruvolo VR, Ligresti G, Martelli AM, Cocco L, Ratti S, Tafuri A, Steelman LS, Candido S, Libra M, McCubrey JA.

Oncotarget. 2017 Aug 24;8(44):76525-76557. doi: 10.18632/oncotarget.20408. eCollection 2017 Sep 29.

8.

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.

Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Mu H, Schober W, Hernandez I, Gallardo M, Khoury JD, Cortes J, Andreeff M, Post SM.

Haematologica. 2017 Dec;102(12):2048-2057. doi: 10.3324/haematol.2017.168856. Epub 2017 Sep 14.

9.

GSK-3 as a novel prognostic indicator in leukemia.

Ruvolo PP.

Adv Biol Regul. 2017 Aug;65:26-35. doi: 10.1016/j.jbior.2017.05.001. Epub 2017 May 8. Review.

PMID:
28499784
10.

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA.

Clin Cancer Res. 2017 Jun 1;23(11):2891-2904. doi: 10.1158/1078-0432.CCR-16-1025. Epub 2016 Nov 30.

11.

Editorial: The Emerging Role for PP2A in Hematologic Malignancies.

Ruvolo PP.

Front Oncol. 2016 Aug 31;6:195. doi: 10.3389/fonc.2016.00195. eCollection 2016. No abstract available.

12.

The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance.

Ruvolo PP.

BBA Clin. 2016 Aug 3;6:87-99. doi: 10.1016/j.bbacli.2016.08.002. eCollection 2016 Dec. Review.

13.

Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.

Piya S, Kornblau SM, Ruvolo VR, Mu H, Ruvolo PP, McQueen T, Davis RE, Hail N Jr, Kantarjian H, Andreeff M, Borthakur G.

Blood. 2016 Sep 1;128(9):1260-9. doi: 10.1182/blood-2016-01-692244. Epub 2016 Jun 7.

14.

Introduction to tumor microenvironment regulation of cancer cell survival, metastasis, inflammation, and immune surveillance.

Semenza GL, Ruvolo PP.

Biochim Biophys Acta. 2016 Mar;1863(3):379-381. doi: 10.1016/j.bbamcr.2015.12.015. Epub 2015 Dec 23. No abstract available.

15.

Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.

Ruvolo PP, Ruvolo VR, Benton CB, AlRawi A, Burks JK, Schober W, Rolke J, Tidmarsh G, Hail N Jr, Davis RE, Andreeff M.

Biochim Biophys Acta. 2016 Apr;1863(4):562-71. doi: 10.1016/j.bbamcr.2015.12.008. Epub 2015 Dec 17.

16.

Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients.

Ruvolo PP, Qiu Y, Coombes KR, Zhang N, Neeley ES, Ruvolo VR, Hail N Jr, Borthakur G, Konopleva M, Andreeff M, Kornblau SM.

BBA Clin. 2015 Jul 23;4:59-68. doi: 10.1016/j.bbacli.2015.07.001. eCollection 2015 Dec.

17.

Galectin 3 as a guardian of the tumor microenvironment.

Ruvolo PP.

Biochim Biophys Acta. 2016 Mar;1863(3):427-437. doi: 10.1016/j.bbamcr.2015.08.008. Epub 2015 Aug 8. Review.

18.

Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.

Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP.

Blood. 2015 Jul 16;126(3):363-72. doi: 10.1182/blood-2014-10-604975. Epub 2015 Jun 4.

19.

The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival.

Lesyk G, Fong T, Ruvolo PP, Jurasz P.

J Thromb Haemost. 2015 Aug;13(8):1514-20. doi: 10.1111/jth.13010. Epub 2015 Jun 17.

20.

The Interplay between PP2A and microRNAs in Leukemia.

Ruvolo PP.

Front Oncol. 2015 Feb 20;5:43. doi: 10.3389/fonc.2015.00043. eCollection 2015. Review.

21.

The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.

Ruvolo PP, Ruvolo VR, Jacamo R, Burks JK, Zeng Z, Duvvuri SR, Zhou L, Qiu Y, Coombes KR, Zhang N, Yoo SY, Pan R, Hail N Jr, Konopleva M, Calin G, Kornblau SM, Andreeff M.

Biochim Biophys Acta. 2014 Sep;1843(9):1969-77. doi: 10.1016/j.bbamcr.2014.05.006. Epub 2014 May 21.

22.

Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM.

Clin Cancer Res. 2014 Apr 15;20(8):2226-35. doi: 10.1158/1078-0432.CCR-13-1978. Epub 2014 Feb 28.

23.

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Müschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG.

Cancer Discov. 2014 Mar;4(3):362-75. doi: 10.1158/2159-8290.CD-13-0609. Epub 2013 Dec 17.

24.

Pharmacologic protein kinase Cα inhibition uncouples human platelet-stimulated angiogenesis from collagen-induced aggregation.

Moncada de la Rosa C, Radziwon-Balicka A, El-Sikhry H, Seubert J, Ruvolo PP, Radomski MW, Jurasz P.

J Pharmacol Exp Ther. 2013 Apr;345(1):15-24. doi: 10.1124/jpet.112.200881. Epub 2013 Feb 5.

PMID:
23386249
25.

The Herculean task of killing cancer cells: suppression of FOXO3A in acute leukemia involves a hydra of multiple survival kinases.

Ruvolo PP.

Cell Cycle. 2012 Jul 15;11(14):2589. doi: 10.4161/cc.21233. Epub 2012 Jul 15. No abstract available.

26.

Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.

Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, Konopleva M, Andreeff M, Kornblau SM.

Leukemia. 2011 Nov;25(11):1711-7. doi: 10.1038/leu.2011.146. Epub 2011 Jun 10.

27.

Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells.

Ruvolo PP, Zhou L, Watt JC, Ruvolo VR, Burks JK, Jiffar T, Kornblau S, Konopleva M, Andreeff M.

J Cell Biochem. 2011 Jun;112(6):1696-707. doi: 10.1002/jcb.23090.

28.

Human glycolipid transfer protein gene (GLTP) expression is regulated by Sp1 and Sp3: involvement of the bioactive sphingolipid ceramide.

Zou X, Gao Y, Ruvolo VR, Gardner TL, Ruvolo PP, Brown RE.

J Biol Chem. 2011 Jan 14;286(2):1301-11. doi: 10.1074/jbc.M110.127837. Epub 2010 Oct 25.

29.

Role for PKC δ in Fenretinide-Mediated Apoptosis in Lymphoid Leukemia Cells.

Ruvolo VR, Karanjeet KB, Schuster TF, Brown R, Deng Y, Hinchcliffe E, Ruvolo PP.

J Signal Transduct. 2010 Jan 1;2010:584657.

30.

Chemopreventive effect of kava on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumorigenesis in A/J mice.

Johnson TE, Kassie F, O'Sullivan MG, Negia M, Hanson TE, Upadhyaya P, Ruvolo PP, Hecht SS, Xing C.

Cancer Prev Res (Phila). 2008 Nov;1(6):430-8. doi: 10.1158/1940-6207.CAPR-08-0027.

31.

PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells.

Ruvolo VR, Kurinna SM, Karanjeet KB, Schuster TF, Martelli AM, McCubrey JA, Ruvolo PP.

J Biol Chem. 2008 Dec 19;283(51):35474-85. doi: 10.1074/jbc.M800951200. Epub 2008 Oct 28.

32.

Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.

Nica AF, Tsao CC, Watt JC, Jiffar T, Kurinna S, Jurasz P, Konopleva M, Andreeff M, Radomski MW, Ruvolo PP.

Cell Cycle. 2008 Nov 1;7(21):3362-70. Epub 2008 Nov 2.

33.

p21 activated kinase 5 activates Raf-1 and targets it to mitochondria.

Wu X, Carr HS, Dan I, Ruvolo PP, Frost JA.

J Cell Biochem. 2008 Sep 1;105(1):167-75. doi: 10.1002/jcb.21809.

34.

Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells.

Kong G, Wang D, Wang H, Wu J, Bielawski J, Konopleva M, Andreeff M, Ruvolo PP, Maurer BJ.

Leukemia. 2008 Jun;22(6):1258-62. Epub 2007 Nov 22. No abstract available.

PMID:
18033322
35.

Mitochondrial protein phosphatase 2A regulates cell death induced by simulated ischemia in kidney NRK-52E cells.

Tsao CC, Nica AF, Kurinna SM, Jiffar T, Mumby M, Ruvolo PP.

Cell Cycle. 2007 Oct 1;6(19):2377-85. Epub 2007 Jul 12.

PMID:
17700073
36.
37.

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M.

Cancer Cell. 2006 Nov;10(5):375-88.

38.

Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML.

Kurinna S, Konopleva M, Palla SL, Chen W, Kornblau S, Contractor R, Deng X, May WS, Andreeff M, Ruvolo PP.

Leukemia. 2006 Jul;20(7):1316-9. Epub 2006 Apr 27. No abstract available.

PMID:
16642043
39.

The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells.

Konopleva M, Contractor R, Kurinna SM, Chen W, Andreeff M, Ruvolo PP.

Leukemia. 2005 Aug;19(8):1350-4.

PMID:
15931262
40.

Ceramide promotes apoptosis in lung cancer-derived A549 cells by a mechanism involving c-Jun NH2-terminal kinase.

Kurinna SM, Tsao CC, Nica AF, Jiffar T, Ruvolo PP.

Cancer Res. 2004 Nov 1;64(21):7852-6.

41.

PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation.

Jiffar T, Kurinna S, Suck G, Carlson-Bremer D, Ricciardi MR, Konopleva M, Andreeff M, Ruvolo PP.

Leukemia. 2004 Mar;18(3):505-12.

PMID:
14737078
42.

Expression of inducible Bcl-X(S) in myeloid leukemia: compensatory upregulation of Bcl-X(L) and Bcl-2 prevents apoptosis and chemosensitization.

Tacke F, Marini FC 3rd, Zhao S, McQueen T, Konopleva M, Ruvolo PP, Hu SX, Xu HJ, Andreeff M.

Cancer Biol Ther. 2004 Mar;3(3):340-7. Epub 2004 Mar 29.

PMID:
14726688
43.

Requirement for SAPK-JNK signaling in the induction of apoptosis by ribosomal stress in REH lymphoid leukemia cells.

Johnson CR, Jiffar T, Fischer UM, Ruvolo PP, Jarvis WD.

Leukemia. 2003 Nov;17(11):2140-8.

PMID:
12970763
44.

Intracellular signal transduction pathways activated by ceramide and its metabolites.

Ruvolo PP.

Pharmacol Res. 2003 May;47(5):383-92. Review.

PMID:
12676512
45.

Protein kinase C-dependent phosphorylation and mitochondrial translocation of aldose reductase.

Varma T, Liu SQ, West M, Thongboonkerd V, Ruvolo PP, May WS, Bhatnagar A.

FEBS Lett. 2003 Jan 16;534(1-3):175-9.

46.

Bryostatin-I: an antineoplastic treasure from the deep?

May WS Jr, Ruvolo PP.

Cancer Biol Ther. 2002 Jul-Aug;1(4):417-9. No abstract available.

PMID:
12432258
47.

A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function.

Ruvolo PP, Clark W, Mumby M, Gao F, May WS.

J Biol Chem. 2002 Jun 21;277(25):22847-52. Epub 2002 Apr 2.

48.
49.

Phosphorylation of Bcl2 and regulation of apoptosis.

Ruvolo PP, Deng X, May WS.

Leukemia. 2001 Apr;15(4):515-22. Review.

50.

Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance.

Deng X, Kornblau SM, Ruvolo PP, May WS Jr.

J Natl Cancer Inst Monogr. 2001;(28):30-7. Review.

PMID:
11158204

Supplemental Content

Loading ...
Support Center